🚀 ** Personalized Melanoma Vaccine Update** Moderna and Merck announced a significant **five-year follow-up** result for their investigational personalized mRNA cancer vaccine, **mRNA-4157 (V940)**, when combined with Merck’s **Keytruda (pembrolizumab)**. The treatment regimen continued to demonstrate a sustained reduction in the risk of **recurrence or death** in patients with **Stage III/IV melanoma** following complete surgical resection. This data solidifies the potential long-term benefit of the personalized neoantigen therapy in the most lethal form of skin cancer. This collaborative effort represents a key advance in **personalized oncology**, moving closer to regulatory submissions for the treatment of high-risk melanoma.